The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes

Nephrology (Carlton). 2010 Apr:15 Suppl 1:S195-203. doi: 10.1111/j.1440-1797.2010.01241.x.
No abstract available

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Chronic Disease
  • Cost-Benefit Analysis
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetic Nephropathies / prevention & control*
  • Diabetic Nephropathies / therapy
  • Humans
  • Kidney Failure, Chronic / prevention & control*
  • Kidney Failure, Chronic / therapy
  • Social Class

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors